Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Altitude Labs, a biotechnology accelerator backed by Recursion Pharmaceuticals, on Wednesday said it is launching a new fund to give pre-seed grants to life sciences researchers and startups disrupted ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...